The multisubunit complex transcription factor IIH (TFIIH) has dual functions in transcriptional initiation and nucleotide excision repair (NER). TFIIH is comprised of two subcomplexes, the core subcomplex (seven subunits) including XPB and XPD helicases and the cyclin-dependent kinase (CDK)-activating kinase (CAK) subcomplex (three subunits) containing CDK7 kinase. Recently, it has been reported that spironolactone, an anti-aldosterone drug, inhibits cellular NER by inducing proteasomal degradation of XPB and potentiates the cytotoxicity of platinum-based drugs in cancer cells, suggesting possible drug repositioning. In this study, we have tried to uncover the mechanism underlying the chemical-induced XPB destabilization. Based on siRNA library screening and subsequent analyses, we identified SCF FBXL18 E3 ligase consisting of Skp1, Cul1, F-box protein FBXL18 and Rbx1 responsible for spironolactone-induced XPB polyubiquitination and degradation. In addition, we showed that CDK7 kinase activity is required for this process. Finally, we found that the Ser90 residue of XPB is essential for the chemical-induced destabilization. These results led us to propose a model that spironolactone may trigger the phosphorylation of XPB at Ser90 by CDK7, which promotes the recognition and polyubiquitination of XPB by SCF FBXL18 for proteasomal degradation.
| INTRODUCTION
Nucleotide excision repair (NER) is one of major DNA repair pathways, which is conserved from bacteria to humans (Marteijn, Lans, Vermeulen, & Hoeijmakers, 2014; Sancar, 1996; Wood, 1996) . NER repairs a variety of helixdistorting DNA lesions; UV-induced 6-4 pyrimidine-pyrimidone photoproducts (6-4PP) as well as cyclobutane pyrimidine dimers (CPD), and bulky base adducts generated by polyaromatic compounds, anticancer drug cisplatin and so on. The NER pathway consists of two subpathways dependent on how DNA lesions are recognized (Schärer, 2013) . Transcription-coupled repair removes DNA lesions in the transcribed DNA strands of active genes, which is initiated by RNA polymerase II stalling at damaged sites (Fousteri & Mullenders, 2008) . On the contrary, global genome repair removes DNA lesions anywhere in the genome that is recognized by UV-DDB complex or XPC complex (Sugasawa et al., 1998; Tang, Hwang, Ford, Hanawalt, & Chu, 2000) . After damage recognition, both subpathways require the recruitment of common NER factors, TFIIH, XPA, RPA, XPG and XPF-ERCC1, to make dual incision bracketing a single DNA lesion, leading to the excision of oligonucleotides (~28-mer). The resultant ssDNA gaps are filled by DNA polymerases in concert with PCNA and RFC and finally sealed to parental strand by DNA ligase (Aboussekhra et al., 1995; Araújo et al., 2000; Mu et al., 1995) .
TFIIH, a ten-subunit complex, functions not only in NER but also transcription as one of basal transcription factors. The TFIIH complex is comprised of the core subcomplex including XPB, XPD, p62, p52, p44, p34 and p8, and the cyclin-dependent kinase (CDK)-activating kinase (CAK) subcomplex including CDK7, Cyclin H and Mat1 (Compe & Egly, 2012) . In the core TFIIH subcomplex, XPB and XPD possess enzymatic activities of ATPase and DNA helicase with opposite polarity (3′-5′ and 5′-3′, respectively), which are involved in local unwinding of duplex DNA around a damaged site or transcriptional initiation site (Evans, Moggs, Hwang, Egly, & Wood, 1997; Fuss & Tainer, 2011; Jiang & Gralla, 1995; Mu, Wakasugi, Hsu, & Sancar, 1997) . The CAK subcomplex plays regulatory roles in transcription, especially promoter clearance by phosphorylating the carboxy-terminal domain (CTD) of Rpb1 subunit of RNA polymerase II, whereas it is dispensable for in vitro NER reaction (Araújo et al., 2000; Feaver, Svejstrup, Henry, & Kornberg, 1994; Lu, Zawel, Fisher, Egly, & Reinberg, 1992; Mu, Hsu, & Sancar, 1996) .
Since TFIIH functions in transcription as well as NER, the cellular level of TFIIH components should be properly regulated within the cells. Recently, Alekseev et al. (2014) have reported that XPB protein is degraded after the treatment with spironolactone, antagonist of aldosterone. As a result, spironolactone-treated cells showed impaired NER and transcriptional activities and higher sensitivity to cisplatin and oxaliplatin, suggesting the possibility of repositioning of spironolactone as an adjuvant for anticancer drugs. It was also shown that the spironolactone-induced XPB degradation depends on ubiquitin-activating enzyme and 26S proteasome. However, the detailed mechanism of this reaction remains to be elucidated.
In this study, we have tried to uncover the molecular mechanism of how XPB is destabilized by spironolactone treatment. Using siRNA library, we found the involvement of FBXL18, one of F-box proteins, in this process. Further analyses showed that the SCF FBXL18 E3 ligase complex consisting of Skp1, Cul1, FBXL18 and Rbx1 polyubiquitinates XPB upon spironolactone treatment. Moreover, we show that CDK7 kinase activity and the Ser90 residue of XPB are also required for this process, suggesting a model that spironolactone may trigger the phosphorylation of XPB at Ser90 by CDK7 and hence its binding to SCF FBXL18 for polyubiquitination and proteasomal degradation.
| RESULTS

| Polyubiquitination and degradation of XPB induced by spironolactone and its derivative compounds
We firstly checked the activity of spironolactone and its derivative compounds, canrenone, SP'-OH (7α-Acetylsulfanyl-3β-hydroxy-17α-pregn-4-ene-21,17-carbolactone) and eplerenone (Figure 1a) , on XPB degradation and NER inhibition using immunoblotting and ELISA, respectively. Canrenone is known as a major metabolite of spironolactone with slightly weaker anti-aldosterone activity. SP'-OH can be generated from the reduction of 3-ketone of spironolactone by Ruche reduction (Gella, Sergienko, & Cherevko, 1994; Li & Zhang, 2007) . Eplerenone is another anti-aldosterone drug with a similar structure to spironolactone and shows higher selectivity to the mineralocorticoid receptor. Consistent with the previous report (Alekseev et al., 2014) , the treatment of spironolactone, but not eplerenone, strongly reduced the cellular level of XPB and attenuated 6-4PP repair (Figure 1b, c) . On the other hand, canrenone was found to completely lack both activities of XPB degradation and NER inhibition, whereas SP'-OH showed weak activities. These results clearly support the notion that the novel activities of spironolactone are independent of its anti-aldosterone activity.
We next tried to detect polyubiquitination of XPB after spironolactone treatment using an in vivo ubiquitination assay. It was suggested that the spironolactone-induced XPB degradation is mediated by the ubiquitin-proteasome pathway, based on its suppression by MG132 (proteasome inhibitor) and PYR-41 (ubiquitin-activating enzyme inhibitor) or siRNA-mediated knockdown of SUG1, a component of proteasome (Alekseev et al., 2014) . HEK293T cells transfected with HA-Ub plasmid were treated with or without spironolactone or canrenone, and cell lysates were immunoprecipitated by anti-HA beads. As shown in Figure 1d , we clearly observed shifted bands of XPB with slower mobility only upon spironolactone treatment and their further enhancement by the addition of MG132. The band shift to higher molecular mass was suppressed with lysine mutant HA-Ub plasmid such as K48R, K63-only or lysine-free (K0), but not K48-only or K63R, suggesting the involvement of K48-linked polyubiquitin chains (Supporting Information Figure S1 ). These results indicate that spironolactone indeed induces polyubiquitination of XPB mainly through a K48 linkage, again independent of anti-aldosterone activity.
| Spironolactone-induced polyubiquitination and degradation of XPB depends on the SCF FBXL18 E3 ligase complex
The ubiquitin-proteasome pathway is known as a major protein degradation system comprised of ubiquitin-activating Genes to Cells
enzymes (E1), ubiquitin-conjugating enzymes (E2), ubiquitin-protein ligases (E3), and the 26S proteasome. We asked which E3 ligase is responsible for the spironolactone-induced XPB polyubiquitination among over 600 kinds of E3 ligases known in mammalian cells. We used a subset of siRNA library (310 siRNAs) including 58 F-box proteins, 42 RING finger proteins (RNFs), 7 Cullins, 5 ubiquitin specific peptidases (USPs) and 4 DCAFs (DDB1-and CUL4-associated factors) (Supporting Information Table  S1 ). After siRNA transfection, MCF-7 cells were treated with 40 µM spironolactone for 4 hr and immunostained with anti-XPB antibody and subsequently Alexa Fluor 488-conjugated secondary antibody. The cellular levels of XPB were analyzed by measuring fluorescence intensity using an image analyzer, leading us to identify F-box protein FBXL18 as a candidate protein involved in spironolactone-induced XPB degradation ( Figure 2a ). We obtained two kinds of siRNAs for FBXL18 and examined their effects on the XPB level by immunoblotting (Figure 2b ) or immunofluorescence staining (Supporting Information Figure S2 ). In both experiments, either of siRNAs showed significant suppression of XPB degradation caused by spironolactone, strongly suggesting that FBXL18 plays some role in this reaction. FBXL18 is one of ~70 F-box proteins and forms the Skp1-Cul1-F-box protein (SCF) E3 ligase complex through the interaction with Skp1 via its amino-terminal F-box domain. We next asked whether the SCF FBXL18 complex is implicated in spironolactone-induced XPB degradation. The E3 ligase activity of SCF complex is known to require neddylation of scaffold protein Cul1, which can be inhibited by NEDD8-activating enzyme (NAE) inhibitor MLN4924 (Soucy et al., 2009) . HeLa cells were treated with spironolactone in the presence or absence of 1 µM MLN4924 for 4 hr. As shown in Figure 2c , MLN4924 markedly suppressed spironolactone-induced XPB degradation. Consistently, the depletion of Cul1 by siRNA also suppressed the XPB degradation ( Figure  2d ). Moreover, in vivo ubiquitination assay showed that spironolactone-induced XPB polyubiquitination is abolished by MLN4924 treatment (Figure 2e ). These results strongly suggest that the SCF FBXL18 complex is involved in the XPB degradation process. We reasoned that FBXL18 would interact with XPB, since the F-box protein functions as a substrate receptor in SCF complex. HeLa cells were transfected with XPB-EGFP or XPB and FBXL18-V5/His expression plasmids, and cell lysates were immunoprecipitated with GFP-Trap beads or anti-V5 beads. In the two reciprocal experiments, each protein was coimmunoprecipitated with immobilized partner protein (Figure 3a,b) , indicating the possible interaction between FBXL18 and XPB.
We further examined whether XPB is a direct substrate for SCF FBXL18 using an in vitro ubiquitination assay.
HEK293T cells were cotransfected with HA-Cul1, HAmRbx1, HA-Skp1 and FBXL18-V5/His constructs, and the SCF FBXL18 complex was purified by immunoprecipitation with anti-V5 beads followed by competitive elution with V5 peptide. Flag-tagged XPB was separately expressed in HEK293T cells and purified with anti-Flag beads and Flag peptide. The two fractions were mixed and incubated with UBE1, UbcH3, Ubc5c, ATP, ubiquitin and ubiquitin aldehyde for 30 min. Immunoblotting with anti-XPB antibody showed strong polyubiquitination signals of XPB ( Figure  3c ), although only marginal in the reaction mixtures with no E3 ligase or the SCF FBXO11 complex similarly prepared (Supporting Information Figure S3 ). These results indicate that the SCF FBXL18 complex has a potential to polyubiquitinate XPB. Taken together, we concluded that the SCF FBXL18 complex is a responsible E3 ligase for the polyubiquitination of XPB upon spironolactone treatment.
| CDK7 kinase activity is required for spironolactone-induced XPB degradation
The binding of F-box protein to its substrate must be tightly regulated and quickly and specifically triggered in response to stimuli. The phosphorylation of substrate is one of triggers and known as phosphodegron (Skaar, Pagan, & Pagano, 2013; Skowyra, Craig, Tyers, Elledge, & Harper, 1997) . The holo TFIIH complex contains XPB in the core subcomplex and CDK7 kinase in the CAK subcomplex. We questioned whether CDK7 may play a role in the process of XPB degradation upon spironolactone treatment. HeLa cells were treated with 0.1 µM THZ1, a specific CDK7 inhibitor, during spironolactone treatment (1-4 hr). As shown in Figure 4a , THZ1 completely abolished XPB degradation caused by spironolactone. Importantly, Ro-3306 and BMS-265246 inhibitors for other CDKs showed no impacts on the degradation (Figure 4b ). Furthermore, siRNA-mediated CDK7 depletion also significantly attenuated the XPB degradation (Figure 4c ). Collectively, we concluded that CDK7 kinase activity is required for the spironolactone-induced XPB degradation.
In order to check the possibility that CDK7 phosphorylates XPB upon spironolactone treatment, we used the Duolink Proximity ligation assay (PLA) technique with anti-phosphoserine (pSer) and anti-XPB antibodies. In the presence of NAE inhibitor MLN4924, PLA signals were dramatically increased upon spironolactone treatment (Figure 4d) , although no signals were observed with either of the two antibodies (Supporting Information Figure S4 ). The signals were strongly reduced by the cotreatment of CDK7 inhibitor THZ1 (Figure 4e) , suggesting a possible model that spironolactone induces the phosphorylation of XPB by CDK7.
| Possible role of Ser90 of XPB in its destabilization caused by spironolactone
Consensus amino acid sequence for CDK7 phosphorylation is a serine-proline (SP) or threonine-proline (TP). XPB is composed of 782 amino acids and contains only two SP and no TP sites as shown in Figure 5a . We decided to generate stable HeLa cell lines expressing wild-type XPB-EGFP or its SA mutants at Ser90 or Ser515. HeLa cells expressing XPB(WT)-EGFP exhibited the comparable degradation of endogenous and exogenous XPB upon spironolactone treatment, which was equally suppressed by CDK7 inhibitor THZ1 (Figure 5b) . A coimmunoprecipitation experiment strongly suggested that the XPB(WT)-EGFP protein is included in the TFIIH holo complex (Figure 5c ), showing that exogenous XPB fused with EGFP behaves itself like endogenous XPB protein. Similarly, exogenous XPB(S515A)-EGFP stably expressed in HeLa cells was also degraded as efficiently as XPB(WT)-EGFP (Figure 5d ). In clear contrast, XPB(S90A)-EGFP was completely resistant to spironolactone-induced degradation, although this mutant XPB is able to form the TFIIH holo complex with other components (Figure 5e ). These results suggest a possible role of the Ser90 residue in XPB destabilization caused by spironolactone. Alekseev et al. (2014) elegantly showed that spironolactone possesses NER inhibitory activity by inducing the proteasomal degradation of XPB subunit of TFIIH, one of essential NER factors, independent from aldosterone antagonist function. It was also shown that the pre-treatment of this compound enhances the cytotoxicity of cisplatin or oxaliplatin in human colon and ovarian carcinoma cells, suggesting its possible drug repositioning as an adjuvant in platinum-based therapy. However, the detail of the mechanism underlying the chemical-induced destabilization of XPB was unknown. In this study, we found that SCF FBXL18 E3 ligase is involved in this process, based on siRNA library screening and subsequent analyses with specific siRNA and inhibitor ( Figures  2 and 3) . Consistently, cellular XPB was polyubiquitinated mainly through a K48 linkage upon the treatment of spironolactone, but not its inactive derivative canrenone (Figure 1d and Supporting Information Figure S1 ), which was markedly attenuated by MLN4924 (Figure 2e ). Moreover, SCF FBXL18 , but not SCF FBXO11 , had the ability to polyubiquitinate XPB in an in vitro ubiquitination assay (Figure 3c ). These results strongly suggest that SCF FBXL18 E3 ligase directly polyubiquitinates XPB in the cells treated with spironolactone, hereby leading to its proteasomal degradation. Second, we showed that CDK7 kinase activity is also required for the spironolactone-induced XPB degradation (Figure 4) . Third, we showed that among two SP sites in XPB, Ser90, but not Ser515, is essential for its degradation induced by spironolactone ( Figure  5) . Collectively, our current model was depicted in Figure 6 , in which spironolactone induces the phosphorylation of XPB at Ser90 by CDK7 kinase (probably as CAK) via currently unclear mechanism, promoting the recognition and K48-linked polyubiquitination of XPB by SCF FBXL18 E3 ligase.
| DISCUSSION
The specific signals with phosphoserine and XPB antibodies as well as their loss after THZ1 treatment in the PLA experiment support this model (Figure 4d,e) . The CAK complex containing CDK7 is known to play multiple roles in transcription and cell cycle regulation (Rimel & Taatjes, 2018) . Two other subunits, Cyclin H and Mat1, appear to have regulatory functions in CDK7 activity and substrate specificity. The CAK complex reversibly associates the TFIIH core subcomplex through the interaction of Mat1 to XPD and XPB (Greber et al., 2017; Luo et al., 2015) . The CAK within TFIIH holo complex phosphorylates Ser5 and Ser7 in the CTD heptad repeats of the largest subunit (Rpb1) of RNA polymerase II, facilitating promoter clearance and also promoter-proximal pausing control. On the other hand, in mammals, CAK is essential for cell cycle progression, independent of the TFIIH core subcomplex, by phosphorylating and activating CDK1, CDK2, CDK4 and CDK6. Whether the possible phosphorylation of XPB by CDK7 upon spironolactone treatment is mediated by CDK7 within the same TFIIH holo complex or CDK7 in the free CAK complex would be an interesting question and needs to await further study.
Another important question is how spironolactone induces CDK7-mediated XPB phosphorylation. It has been reported that natural product triptolide covalently binds to Cys342 of XPB and inhibits its ATPase activity, resulting in suppression of transcription and NER (He et al., 2015; Titov et al., 2011) . Interestingly, at higher concentrations or longer exposure, the compound causes proteasomal degradation of Rpb1 subunit of RNA polymerase II (Wang, Lu, He, & Yu, 2011) , by activating CDK7 kinase for the hyperphosphorylation of Ser5 in the CTD heptad repeats (Manzo et al., 2012) . The authors speculated that the binding of triptolide to XPB might cause conformational change, which leads to CDK7 activation. The identification of a primary cellular target of spironolactone will help us to understand several black boxes remaining in this reaction.
Another key player FBXL18 belongs to a subfamily (FBXL) of F-box proteins that contain a carboxy-terminal leucine-rich repeat motif, in addition to an amino-terminal F-box motif. In the literature, SCF FBXL18 E3 ligase appears to play some role in the regulation of Akt, LRRK2 and FBXL7 (Ding, Barodia, Ma, & Goldberg, 2017; Liu et al., 2015; Zhang et al., 2017) . Notably, FBXL7, another FBXL subfamily member, was shown to bind to FBXL18 via Phe67-Gln68 (FQ motif) and ubiquitinated at Lys109 by SCF FBXL18 for proteasomal degradation. However, there is no FQ motif in XPB protein and the cellular level of FBXL7 was not affected upon spironolactone treatment (Supporting Information Figure S5 ), suggesting independent mechanisms of SCF FBXL18 -mediated protein destabilization. Therefore, SCF FBXL18 E3 ligase itself would not be a direct target for spironolactone. Recently, various types of small molecule compounds targeting specific proteins for proteasomal degradation have been reported and have important implications in their application to anticancer agents. A most representative example would be thalidomide and its derivatives (e.g., lenalidomide and pomalidomide), which bind to CRBN, one of substrate receptors for the Cul4-Rbx1-DDB1 E3 ligase complex, and modulate its substrate specificity (Gandhi et al., 2014; Ito et al., 2010; Krönke et al., 2014; Lu et al., 2014) . The binding of lenalidomide or pomalidomide to CRBN efficiently promotes the interaction of CRBN with two lymphoid transcription factors, IKZF1 and IKZF3, and their proteasomal degradation, hereby exhibiting dramatic clinical efficacy in multiple myeloma. The small compounds inducing targetprotein degradation has a great potential for multiple applications to not only clinical drugs but also experimental tools for mechanistic analyses by specific protein knockdown. The accumulating knowledge of the mechanisms of chemical-mediated protein destabilization would be helpful for further expansion of this concept and technology.
| EXPERIMENTAL PROCEDURES
| Cell culture and chemicals
HeLa and HEK293T cell lines were cultured in Dulbecco's modified Eagle's medium (Wako) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 50 µg/ml Gentamicin (Nacalai tesque) at 37°C in a humidified incubator under 5% CO 2 . MCF-7 cells were cultured in Minimum Essential Medium Eagle Alpha Modification (Sigma-Aldrich) supplemented with 2 mM l-Glutamine (Thermo Fisher Scientific) and 10% fetal bovine serum (Nichirei Bioscience) at 37°C in a humidified incubator under 5% CO 2 .
Spironolactone and eplerenone were purchased from Wako and TCI, respectively. Canrenone and SP were synthesized from spironolactone according to the literature (Gella et al., 1994; Larik et al., 2017; Li & Zhang, 2007; Wishart et al., 2009) . Briefly, for canrenone, spironolactone (41.7 mg, 0.1 mmol) was dissolved in DMF and stirred with K 2 CO 3 (16.4 mg, 0.12 mmol) for 1 hr at 60°C. For SP spironolactone (41.7 mg, 0.1 mmol) and CeCl 3 ·7H 2 O (44.7 mg, 0.12 mmol) were dissolved in anhydrous methanol under a nitrogen atmosphere, and the mixture was stirred at 0°C for 10 min after adding NaBH 4 (1.9 mg, 0.05 mmol) (Ruche reduction). After quenching the reaction and extracting with ethyl acetate, canrenone (33.2 mg, 0.098 mmol) or SP'-OH (37.8 mg, 0.090 mmol) was purified by flash chromatography. The structures of both compounds were confirmed by 1 H and 13 C NMR.
Various inhibitors were purchased from the manufacturers as follows: MG132 (Peptide Institute), MLN4924 (Merck-Millipore), THZ1 (Cayman Chemical), Ro-3306 (Chemscene) and BMS-265246 (Adooq Bioscience Clinisciences). In all experiments with the inhibitors, cells were pre-treated with inhibitor(s) 1 hr prior to the addition of spironolactone.
| Antibodies
Anti-XPB (S-19, cat. no. sc-293), anti-CDK7 (C-19, cat. no. sc-529), anti-Cyclin H (C-18, cat. no. sc-609), anti-Mat1 (FL-309, cat. no. sc-6234) and anti-Cul1 (D-5, cat. no. sc-17775) antibodies were obtained from Santa Cruz Biotechnology. Anti-XPD (cat. no. A303-658A), anti-FBXL18 (cat. no. ab220107) and anti-V5 (cat. no. 46-0705) antibodies were purchased from Bethyl Laboratories, Abcam and Invitrogen, respectively. Anti-XPB (15TF2-1B3, cat. no. MABE1123) and antiphosphoserine (pSer) (clone 4A4, cat. no. 05-1000) antibodies were from Merck-Millipore, and anti-HA (cat. no. 561) and anti-GFP (cat. no. 598) antibodies were from MBL.
| Immunoblotting
Cells were lysed in 1% NP-40 Lysis buffer (10 mM TrisHCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5 mM EDTA) supplemented with cOmplete™ EDTA-free Protease Inhibitor Cocktail (Roche) for 30 min on ice. The cell lysates were centrifuged at 13,200 rpm (16,100 g) for 15 min at 4°C, and protein concentrations of supernatant were determined by Protein Assay Dye Reagent Concentrate (BioRad). Aliquots of cell lysates were mixed with 6× sample buffer for SDS-PAGE (Nacalai tesque) supplemented with 5% 2-mercaptoethanol (Thermo Fisher Scientific) and boiled at 100°C for 3 min. After SDS-PAGE and electrotransfer to Immobilon-P membranes (Merck-Millipore), proteins were reacted with various primary antibodies and then horseradish peroxidase (HRP)-conjugated secondary antibody. The immunoblot signals were visualized by Immobilon Western Chemiluminescent HRP substrate (Merck-Millipore) and detected with the ImageQuant LAS4000 (Fuji Film).
| Enzyme-linked immunosorbent assay (ELISA)
Cells seeded on 60-mm dishes were irradiated with or without UV-C (10 J/m 2 ) from germicidal lamps (Toshiba, GL-10) and incubated for various repair periods. Genomic DNAs were purified with the Geno Plus™ Genomic DNA Extraction Miniprep Genes to Cells UEDA Et Al.
System (VIOGENE), and the amounts of 6-4PP were measured using anti-6-4PP monoclonal antibody (64M-5) as described previously (Matsumoto et al., 2007; Mori et al., 1991) .
| siRNA library screening
Cells were seeded on 384-well microplate (CellCarrier Ultra, PerkinElmer) and treated with 3 nM siRNAs (Silencer Select 3 siRNAs/pool, Thermo Fisher Scientific) and 0.025 µl Lipofectamine™ RNAiMAX Transfection Reagent (Thermo Fisher Scientific) for 48 hr. Cells were washed with cold PBS(−) twice, fixed with 4% paraformaldehyde (SigmaAldrich) in PBS(−) for 30 min at room temperature and permeabilized by 0.5% Triton X-100 in 10 mM PBS for 20 min at room temperature. After fixation, the cells were blocked with 1% BSA in 10 mM PBS and incubated with anti-XPB (15TF2-1B3) antibody and subsequently Alexa Fluor™ 488 goat anti-rabbit IgG (H + L) conjugate (Thermo Fisher Scientific). After counterstaining with Hoechst 33342 (Thermo Fisher Scientific), the fluorescent signals were detected and analyzed by Opera Phenix and Harmony (PerkinElmer).
| Plasmids and siRNAs
pcDNA3.1D/FBXL18-V5/His plasmid was a kind gift from Dr. Rama K. Mallampalli . pEF6/HA-Cul1, pEF6/HA-mRbx1 and pEF6/HA-Skp1 constructs were kindly provided by Dr. Katsumi Yamashita (Uchida et al., 2011) . pCGN/HA-Ubiquitin (HA-Ub) plasmid was obtained from Dr. Mizuho Hasegawa (Hasegawa et al., 2008) . XPB cDNA was a generous gift from Dr. Aziz Sancar and subcloned into pEF6/ myc-His or pEGFP-N3 vector. The expression plasmids for mutant XPB (S90A or S515A) were generated by PCR with primer pairs, TTGGAAGCCTTCGCTCCAGTTTACAAA (forward) and TTTGTAACTGGAGCGAAGGCTTCCAA (reverse) or TGGTGCCCTATGGCTCCTGAATTTTAC (forward) and GTAAAATTCAGGAGCCATAGGGCACCA (reverse) (The underlines indicate the sequence corresponding to each amino acid substitution.), respectively, followed by subcloning.
The siRNAs for FBXL18 #1 (5′-CUGCAGCACAUG AAAUUCAdTdT-3′), FBXL18 #2 (5′-ACACCGUGUU GCUGCAAAAdTdT-3′), Cul1 (5′-CAGGUUUACCUUC AUGAAAdTdT-3′) and CDK7 (5′-CAGUGGAAACCUU AAAGGAdTdT-3′) were purchased from Sigma-Aldrich and transfected into HeLa cells using Lipofectamine™ RNAiMAX Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer's instruction.
| Immunoprecipitation
pEGFP-N3 or pEGFP-N3/XPB plasmid was cotransfected with pcDNA3.1D/FBXL18-V5/His into HeLa cells using PEI-Max transfection reagent (Polysciences, Inc.) according to the manufacturer's instruction. Cell lysates were prepared with 1% NP-40 Lysis buffer as described above and incubated with GFP-Trap ® _MA beads (ChromoTek) or Anti-V5-tag mAb-Magnetic Beads (M215-11) (MBL) for 1 hr at 4°C. After washing the beads with 1% NP-40 Lysis buffer, bound fraction was eluted by heating for 10 min at 100°C in sample buffer for SDS-PAGE supplemented with 5% 2-mercaptoethanol and analyzed by immunoblotting.
| In vivo ubiquitination assay
HEK293T cells were transfected with pCGN/HA-Ub plasmid for 24 hr and treated with spironolactone (20 µM) for 4 hr in the presence or absence of MG132 (10 µM) or MLN4924 (3 µM). The cells were lysed with Dilution buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA) and boiled at 100°C for 10 min after the addition of 2% SDS solution (final 0.5%). Following sonication and twofold dilution with Dilution buffer, the lysates were centrifuged at 13,200 rpm (16,100 g) for 15 min at 4°C and the resultant supernatants were incubated with Anti HA Antibody Beads (Wako) for 3 hr at 4°C. After washing the beads with 1% NP-40 wash buffer (50 mM Tris-HCl, pH 7.4, 1 M NaCl, 1% Nonidet P-40, 1 mM EDTA), bound fraction was eluted by heating for 10 min at 100°C in sample buffer supplemented with 5% 2-mercaptoethanol and analyzed by immunoblotting with anti-XPB (S-19) antibody.
| In vitro ubiquitination assay
To isolate the SCF FBXL18 or SCF FBXO11 E3 ligase complex, HA-mRbx1, HA-Skp1, HA-Cul1 and FBXL18-V5-His or Flag-FBXO11 were transiently expressed in HEK293T cells for 48 hr and immunoprecipitated with Anti-V5-tag mAbMagnetic Beads (M215-11) (MBL) or Anti-DYKDDDDK tag Antibody Beads (Wako), respectively. Flag-XPB was separately expressed in HEK293T cells for 48 hr and isolated with Anti-DYKDDDDK tag Antibody Beads. The bound fractions were eluted with V5 or Flag peptide (0.2 mg/ ml peptide in TBS buffer) and mixed in a total volume of 30 µl reaction buffer (50 mM Tris-HCl, 5 mM MgCl 2 , pH 7.4) containing UBE1 (0.1 µM), UbcH3 (0.25 µM), Ubc5c (0.25 µM), ATP (2 mM), ubiquitin (1.5 µg/µl) and ubiquitin aldehyde (1 µM) (Boston Biochem). The mixture was incubated for 30 min at 37°C and boiled for 10 min at 100°C after adding 6 µl of 6× sample buffer for SDS-PAGE supplemented with 5% 2-mercaptoethanol.
| Proximity ligation assay
The proximity ligation assay was conducted using a Duolink Detection Kit (Sigma-Aldrich) according to the manufacturer's instructions. Briefly, HeLa cells seeded on 35-mm dishes containing a glass coverslip were incubated for 24 hr and treated with spironolactone (20 µM) for 4 hr in the presence or absence of MLN4924 (1 µM) and/ or THZ1 (0.1 µM). After washing with cold PBS(-) twice, the cells were fixed with 10% formalin solution (Wako) for 15 min at room temperature and permeabilized with 1% Triton X-100 in 10 mM PBS for 5 min on ice. The combination of primary antibodies used in this study was anti-pSer (clone 4A4) and anti-XPB (S-19). After counterstaining with DAPI, PLA signals were detected with the LSM710 confocal microscope (Carl Zeiss). 
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